LOW-DOSE SIROLIMUS FOR NOSEBLEEDS IN HHT: A PHASE II PILOT STUDY

Registry ID

200421448

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ST MICHAELS HOSPITAL

Last update

2021-09-08

Conditions

• HEREDITARY HAEMORRHAGIC TELANGIECTASIA

Related clinical trials

• A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2-PART STUDY OF THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE DOSE ALN-6400 IN ADULT HEALTHY VOLUNTEERS AND MULTIPLE DOSE ALN-6400 IN ADULT PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
• DOXYCYCLINE CROSSOVER TRIAL FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

View on source registry